search

Active clinical trials for "Sarcoma, Ewing"

Results 111-120 of 248

Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma

Ewing's Sarcoma

Controlled, randomized phase III study, with the intent of optimizing the treatment of not metastatic Ewing Sarcoma. The patients will be randomized into 2 arms: standard treatment vs intensive treatment. Both arms will receive an induction treatment followed by surgery (wherever is possible) and/or radiotherapy. The maintenance treatment will be different on the basis of the response to the induction treatment (good or poor)

Completed15 enrollment criteria

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With...

Rhabdomyosarcoma and Other Soft Tissue SarcomasEwing's Sarcoma Family of Tumors3 more

The purpose of this study is to determine the safest and most effective oral dose combinations of sorafenib and irinotecan in pediatric patients with solid tumors, i.e. relapsed or refractory.

Completed54 enrollment criteria

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Ewing's Sarcoma

This research study is a Phase II clinical trial to test the efficacy of Olaparib in adult participants with recurrent/metastatic Ewing's Sarcoma following failure of prior chemotherapy.

Completed22 enrollment criteria

Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

Ewing's Sarcoma

Primary Objectives: To determine the feasibility and toxicity profile of administering liposomal 9-Nitro-20-(S)-Camptothecin (L9-NC) by aerosol alone and in combination with temozolomide. To determine the effectiveness of L9-NC given by aerosol in combination with temozolomide in patients with solid tumors involving the lungs.

Completed11 enrollment criteria

Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors

Ewing's Sarcoma Family of Tumors

Define the efficacy of CP-751,871 in patients with Ewing's sarcoma family of tumors

Completed4 enrollment criteria

QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic...

Askin's TumorsDesmoplastic Small Round Cell Tumors5 more

Single-arm, open-label study of AMG 479 in up to 35 subjects with Ewing's Family Tumors (EFTs) and Desmoplastic Small Round Cell Tumors (DSRCTs) who have progressed or recurred after at least one prior chemotherapy regimen. An exploratory cohort of an additional up to 10 subjects with prior exposure to anti-IGF-1R therapy and who have progressed or recurred after at least one prior chemotherapy regimen will also be assessed.

Completed38 enrollment criteria

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Adult RhabdomyosarcomaAdult Synovial Sarcoma14 more

This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.

Completed59 enrollment criteria

Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or...

Sarcoma

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have relapsed or refractory Ewing's sarcoma or peripheral primitive neuroectodermal tumor or desmoplastic small round cell tumor.

Completed59 enrollment criteria

A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive...

Neuroectodermal TumorPrimitive5 more

This protocol is designed to test the feasibility of the administration of vincristine, adriamycin and cytoxan, alternating with the newly developed regimen ifosfamide VP-16 as well as the efficacy of this therapy in addition to radiotherapy in producing complete responses and disease-free survival in patients with Ewing's sarcoma, primitive sarcoma of bone, peripheral neuroepithelioma, and soft tissue sarcoma. This will not be a randomized study but will be comparable to the large data base of similar patients treated on successive Pediatric Branch studies.

Completed6 enrollment criteria

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation...

Ewing's SarcomaRhabdomyosarcoma

Arm A: Peripheral blood apheresis by harvesting chemotherapy-naive T cells and populations enriched for professional APCs. T cells and APCs are separated from the apheresis product using countercurrent centrifugal elutriation and a monocyte rich fraction is collected. Autologous T cell transplantation during immunotherapy. Arm B: Cell harvesting is performed as soon as possible. Both Arm A and B: Patients receive intravenous infusion of irradiated peptide-pulsed antigen presenting cell vaccination (APC) products as well as intramuscular injection of influenza vaccine on the same day. Recombinant human IL-2 is administered within 4 hours of the peptide pulsed vaccine by continuous intravenous infusion for 4 days per week for 3 successive weeks. Primary toxic effect of this therapy is expected to be related to the IL-2 therapy. Patients with Grade 2 neurologic or cardiac or any Grade 3 or 4 toxic effects will discontinued IL-2 therapy. If toxic effect is not resolved in 72-hours, the patient may remain on study but will not receive any further IL-2.

Completed17 enrollment criteria
1...111213...25

Need Help? Contact our team!


We'll reach out to this number within 24 hrs